PROPANC BIOPHARMA INC(NASDAQ:PPCB) stock News

PPCB Latest News, Press Relases and Analysis

All

Press Releases

15 days ago - By: Propanc Biopharma, Inc.

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

15 days ago - By: Propanc Biopharma, Inc.

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

a month ago - By: Benzinga - Mentions: BRKR SLRX LUNG HOTH ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

a month ago - By: Propanc Biopharma, Inc.

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

a month ago - By: Stocktwits

Why Propanc stock Is Tumbling In Premarket Today

a month ago - By: Benzinga - Mentions: MTNB TPIC RSKD VTAK ...

US Stocks Mixed; Riskified Shares Dip After Q2 Results

a month ago - By: Propanc Biopharma, Inc.

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

a month ago - By: ACCESS Newswire

D. Boral Capital Acted as Lead Bookrunner to Propanc Biopharma, Inc. (Nasdaq:PPCB) in Connection with its $4,000,000 Uplisting

a month ago - By: Propanc Biopharma, Inc.

Propanc Biopharma Provides Shareholder Update

a month ago - By: Propanc Biopharma, Inc.

Propanc Biopharma Provides Shareholder Update

a month ago - By: Propanc Biopharma, Inc.

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

a month ago - By: Propanc Biopharma, Inc.

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

2 months ago - By: Propanc Biopharma, Inc.

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

2 months ago - By: Propanc Biopharma, Inc.

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

a year ago - By: Propanc Biopharma, Inc. - Mentions: OTC

Propanc Biopharma’s Peer Reviewed Articles for Proenzymes Cancer Treatment Generates “Unprecedented” Interest

a year ago - By: Propanc Biopharma, Inc. - Mentions: OTC

Propanc Biopharma Receives Notice of Allowance for “Proenzyme Composition” Patent in North America

a year ago - By: Propanc Biopharma, Inc. - Mentions: OTC

Propanc Biopharma’s CSO Predicts PRP Could Solve Problem That Impacts Response Rate of Immune Checkpoint Inhibitors Treating Solid Tumors

a year ago - By: Propanc Biopharma, Inc. - Mentions: OTC

Propanc Biopharma Receives Certificate of Grant for “Proenzymes Composition” Patent from Japanese Patent Office

a year ago - By: Propanc Biopharma, Inc. - Mentions: OTC

Propanc Biopharma Receives Certificate of Grant for “Composition of Proenzymes for Cancer Treatment” Patent from European Patent Office

1 years ago - By: Propanc Biopharma - Mentions: OTC

Propanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic Financing

2 years ago - By: Propanc Biopharma, Inc - Mentions: OTC

Propanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use Study

2 years ago - By: Propanc Biopharma, Inc. - Mentions: OTC

Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office

2 years ago - By: Propanc Biopharma, Inc. - Mentions: OTC

Propanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment Opportunities

2 years ago - By: Propanc Biopharma, Inc. - Mentions: OTC

Propanc Biopharma’s Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRP

2 years ago - By: Propanc Biopharma, Inc. - Mentions: OTC

PROPANC BIOPHARMA INC (PPCB) Stock News

PPCB Latest News, Press Relases and Analysis

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

12 Health Care Stocks Moving In Tuesday's After-Market Session

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

Why Propanc stock Is Tumbling In Premarket Today

US Stocks Mixed; Riskified Shares Dip After Q2 Results

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

D. Boral Capital Acted as Lead Bookrunner to Propanc Biopharma, Inc. (Nasdaq:PPCB) in Connection with its $4,000,000 Uplisting

Propanc Biopharma Provides Shareholder Update

Propanc Biopharma Provides Shareholder Update

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

Propanc Biopharma’s Peer Reviewed Articles for Proenzymes Cancer Treatment Generates “Unprecedented” Interest

Propanc Biopharma Receives Notice of Allowance for “Proenzyme Composition” Patent in North America

Propanc Biopharma’s CSO Predicts PRP Could Solve Problem That Impacts Response Rate of Immune Checkpoint Inhibitors Treating Solid Tumors

Propanc Biopharma Receives Certificate of Grant for “Proenzymes Composition” Patent from Japanese Patent Office

Propanc Biopharma Receives Certificate of Grant for “Composition of Proenzymes for Cancer Treatment” Patent from European Patent Office

Propanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic Financing

Propanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use Study

Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office

Propanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment Opportunities

Propanc Biopharma’s Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRP

Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor Cells